Carl KestensFeb 26, 20228 min TIML/INKMUNE MAY DRASTICALLY OUTPERFORM CIML – A COMPARISONReminder of the NK cell activation threshold as a predictor of survival This, we know. · INKmune generates memory-like NK cells in...
Carl KestensFeb 20, 202216 minINKMUNE AS A NEW APPROACH IN NK-TARGETING IMMUNO-ONCOLOGYSummary: INKmune is an NK-targeting immuno-oncology drug allowing treatment in a wide range of NK-related cancers; INKmune’s production...
Carl KestensJan 23, 202213 minTHE TEN BILLION UNICORN IN INMB: ON MY INVESTMENT THESIS AND INMB’s PRICE MOVEMENTS In my mind's eye, these stairs keep on going into 2023 and the years after. INTRODUCTION The previous five blogs have laid out the...
Carl KestensDec 29, 202110 minTHE TEN BILLION DOLLAR UNICORN IN INMUNE BIO, PART IV: A DEEPER DIVE INTO INKMUNEThe immuno-oncology platform INKmune of INmune Bio may be a better, easier to produce and cheaper product candidate than others.
Carl KestensDec 21, 202114 minTHE TEN BILLION DOLLAR UNICORN IN INMUNE BIO, PART III: AN INTRODUCTION TO INKMUNEINTRODUCTION As an immunotherapy drug candidate, INKmune seems by far the most commercially sustainable, undervalued that I am aware of....